Simvastatin and bone marrow-derived mesenchymal stem cells (BMSCs) affects serum IgE and lung cytokines levels in sensitized mice

Mohammadian, Maryam; Sadeghipour, Hamid Reza; Jahromi, Gila Pirzad; Jafari, Mahvash; Nejad, A K Khoshkhoo; Khamse, Safoura; Boskabady, Mohammad Hossein

doi:10.1016/j.cyto.2018.06.016

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study demonstrated that IL-13 levels in BALF supernatants were significantly higher in the asthma group compared to the control group. This observation is in accordance with the studies of Mohammadian et al (2019) that reported an increase in IL-13 levels with asthma induction.…”

Section: Discussionsupporting

confidence: 93%

“…For induction of a chronic model of asthma in mice, a protocol of immunization with OVA was used (Mohammadian et al 2016(Mohammadian et al , 2019Kianmehr et al 2016Kianmehr et al , 2017Kianian et al 2019aKianian et al , 2019b. Briefly, except animals in the control group, others were sensitized by intraperitoneal injection of 10 mg OVA and 2 mg aluminium hydroxide (Sigma, USA) on days 0 and 14.…”

Section: Experimental Designmentioning

confidence: 99%

See 1 more Smart Citation

Protective effects of ascorbic acid and calcitriol combination on airway remodelling in ovalbumin-induced chronic asthma

Kianian

Karimian

Kadkhodaee

et al. 2020

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

Context: Airway remodelling is one of the most refractory problems in asthma. According to the critical roles of oxidative stress and inflammation in airway remodelling, it is supposed that ascorbic acid and calcitriol have beneficial effects. However, a combination of antioxidants may be more effective for asthma therapy. Objective: This study investigated the protective effects of ascorbic acid in combination with calcitriol on airway remodelling in ovalbumin (OVA)-induced chronic asthma. Materials and methods: BALB/c mice were assigned into seven groups: (1) Control; (2) Asthma; (3) Ineffective C (orally 39 mg/kg ascorbic acid); (4) Ineffective D (intraperitoneally 1.5 lg/kg calcitriol); (5) Effective C (orally 130 mg/kg ascorbic acid); (6) Effective D (intraperitoneally 5 lg/kg calcitriol); (7) Combination (orally 39 mg/kg ascorbic acid þ intraperitoneally 1.5 lg/kg calcitriol). All animals were sensitized and challenged with OVA except in the control group (normal saline). In all treatment groups, mice were administrated vitamins 30 min before each challenge (three times per week for 8 consecutive weeks). Results: In comparison with the asthma group, co-administration of ineffective doses of ascorbic acid and calcitriol led to the decreased levels of IL-13 (50.5 ± 1.85 vs. 42.13 ± 0.37 pg/mL, p ¼ 0.02) and IgE (58.74 ± 0.43 vs. 45.78 ± 2.05 ng/mL, p ¼ 0.003) as well as the reduction of goblet hyperplasia and subepithelial fibrosis (5 vs. 1 score, p ¼ 0.001 and 5 vs. 2 score, p ¼ 0.001, respectively). Discussion and conclusions: Combination of ascorbic acid with calcitriol in ineffective doses improves airway remodelling due to additive effects possibly through reduction of oxidative stress and inflammation. This study provides a scientific basis for further research and clinical applications of ascorbic acid and calcitriol and can be generalized to the broader pharmacological studies.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Experimental Designmentioning

confidence: 99%

Protective effects of ascorbic acid and calcitriol combination on airway remodelling in ovalbumin-induced chronic asthma

Kianian

Karimian

Kadkhodaee

et al. 2020

Pharmaceutical Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…An experimental study by Mohammadian et al in 2018 demonstrated that a single infusion of simvastatin in combination with BM-MSCs could remarkably reduce serum total and specific IgE, as well as lung IL-13 and TGF-β levels in ovalbumin-induced murine models of asthma as compared with simvastatin alone. The excellent effects of combination therapy may be because of elevation of BM-MSC migration to lung [ 63 ]. In another work, immunoregulatory effects of BM-MSCs and mitochondrial signaling pathways was investigated in asthmatic mice model through both intratracheal and systemic routs.…”

Section: Various Mscs In Treatment Of Copd and Asthmamentioning

confidence: 99%

Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools

et al. 2022

View full text Add to dashboard Cite

Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, are one of the most frequent causes of morbidity and mortality in the global. COPD is characterized by progressive loss of lung function through inflammation, apoptosis, and oxidative stress caused by chronic exposure to harmful environmental pollutants. Airway inflammation and epithelial remodeling are also two main characteristics of asthma. In spite of extensive efforts from researchers, there is still a great need for novel therapeutic approaches for treatment of these conditions. Accumulating evidence suggests the potential role of mesenchymal stem cells (MSCs) in treatment of many lung injuries due to their beneficial features including immunomodulation and tissue regeneration. Besides, the therapeutic advantages of MSCs are chiefly related to their paracrine functions such as releasing extracellular vesicles (EVs). EVs comprising exosomes and microvesicles are heterogeneous bilayer membrane structures loaded with various lipids, nucleic acids and proteins. Due to their lower immunogenicity, tumorigenicity, and easier management, EVs have appeared as favorable alternatives to stem cell therapies. Therefore, in this review, we provided an overview on the current understanding of the importance of MSCs and MSC-derived EVs from different sources reported in preclinical and clinical COPD and asthmatic models.

show abstract

Current therapeutic strategies for respiratory diseases using mesenchymal stem cells

Wang

Zhou

Zhang

et al. 2021

MedComm

View full text Add to dashboard Cite

Mesenchymal stromal/stem cells (MSCs) have a great potential to proliferate, undergo multi‐directional differentiation, and exert immunoregulatory effects. There is already much enthusiasm for their therapeutic potentials for respiratory inflammatory diseases. Although the mechanism of MSCs‐based therapy has been well explored, only a few articles have summarized the key advances in this field. We hereby provide a review over the latest progresses made on the MSCs‐based therapies for four types of inflammatory respiratory diseases, including idiopathic pulmonary fibrosis, acute respiratory distress syndrome, chronic obstructive pulmonary disease, and asthma, and the uncovery of their underlying mechanisms from the perspective of biological characteristics and functions. Furthermore, we have also discussed the advantages and disadvantages of the MSCs‐based therapies and prospects for their optimization.

show abstract

Simvastatin and bone marrow-derived mesenchymal stem cells (BMSCs) affects serum IgE and lung cytokines levels in sensitized mice

Cited by 6 publications

References 29 publications

Protective effects of ascorbic acid and calcitriol combination on airway remodelling in ovalbumin-induced chronic asthma

Protective effects of ascorbic acid and calcitriol combination on airway remodelling in ovalbumin-induced chronic asthma

Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools

Current therapeutic strategies for respiratory diseases using mesenchymal stem cells

Contact Info

Product

Resources

About